Molecular Contrast Agents Based on Gold Nanocages for OCT Imaging of Cancer

基于金纳米笼的分子造影剂用于癌症 OCT 成像

• 批准号: 7430270
• 负责人: Xingde Li
• 金额: $ 26.29万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7430270
• 关键词: Algorithms; Animal Model; Antibodies; Biomedical Engineering; Biomedical Technology; Biopsy; Blinded; Cancer Model; Carcinoma; Cell surface; Cheek structure; Chemistry; Class; Clinical; Condition; Contrast Media; Detection; Diagnostic; Dysplasia; Esophagectomy; Excision; Exhibits; Extracellular Matrix; Gold; Hamsters; Histology; Human; Image; Imaging technology; Inherited; Invasive; Length; Malignant Neoplasms; Measures; Medicine; Metaplasia; Microanatomy; Molecular; Neoplasm Metastasis; Neoplasms; Normal tissue morphology; Optical Biopsy; Optical Coherence Tomography; Optics; Organ; Pathology; Patients; Production; Property; Range; Rate; Reaction; Research Personnel; Resolution; Sampling Errors; Screening for cancer; Series; Silver; Specificity; Specimen; Spectrum Analysis; Standards of Weights and Measures; Survival Rate; System; Techniques; Time; Tissues; Topical application; Treatment outcome; Universities; Washington; absorption; antibody conjugate; base; cancer diagnosis; cancer imaging; cancer surgery; carcinogenesis; experience; gold tetrachloride, acid; improved; in vivo; interest; molecular recognition; multidisciplinary; nano; nanoparticle; novel; optical imaging; programs; scale up; size; success; tomography

DESCRIPTION (provided by applicant): This proposal is a multidisciplinary program involving researchers from the Departments of Bioengineering, Chemistry, Pathology and Medicine at the University of Washington. The objective is to develop and validate a new class of molecular nano contrast agents based on biocojugatible gold nanocages for improving the ability of optical coherence tomography (OCT) in early cancer detection. Cancers develop over a period of several years and experience molecular and structural changes prior to metastasis. Early cancer detection remains a critical clinical objective to improve survival rates and treatment outcomes. OCT is a recently developed non-invasive technique that can perform "optical biopsy" by cross-sectional imaging of tissue microanatomy in vivo and in real time. OCT offers excellent spatial resolution; however, currently it has limited success in early cancer detection mainly because of the weak intrinsic optical contrast between normal tissue and early cancer and its lack of molecular specificity. The hypothesis of this proposal is that novel molecular contrast agents can enhance OCT imaging contrast and molecular specificity for early cancer detection. Unlike other metallic nanoparticles, gold nanocages exhibit very strong, tunable optical resonance in the near infrared range while remaining a small size (35-65 nm). Gold nanocages can provide both intensity and spectroscopic contrast enhancement for OCT imaging and they permit facile conjugation of molecular recognition agents for targeting. The specific aims are to: (1) develop gold nanocages with strong absorption or scattering in the near-infrared range using galvanic replacement nanochemistry and optimize synthesis conditions for scaling-up production; (2) characterize the optical properties of nanocages, compare the results with theoretical calculations based on discrete dipole approximation, and quantify intensity and spectroscopic OCT contrast enhancement; (3) perform in vivo animal model studies to quantitatively evaluate the ability of OCT for early cancer detection with assistance of bioconjugated nanocages; and (4) investigate the ability of OCT in detecting dysplasia and early cancer on human esophagectomy specimens using molecular contrast agents. If successful, molecular contrast enabled OCT can improve our ability to detect early cancers, guide biopsy and cancer surgery. In addition, the molecular contrast agents can also be used for other optical imaging and spectroscopy techniques.

描述（由申请人提供）：该计划是一个多学科计划，涉及华盛顿大学生物工程、化学、病理学和医学系的研究人员。我们的目标是开发和验证一类新的分子纳米造影剂的基础上，生物共轭金纳米笼，以提高光学相干断层扫描（OCT）在早期癌症检测的能力。癌症发展经过数年的时间，并在转移之前经历分子和结构变化。早期癌症检测仍然是提高生存率和治疗结果的关键临床目标。光学相干断层扫描（OCT）是近年来发展起来的一种非侵入性技术，它可以通过对活体组织的显微解剖结构进行真实的实时的横截面成像来进行“光学活检”。OCT提供了优异的空间分辨率;然而，目前它在早期癌症检测中的成功有限，主要是因为正常组织和早期癌症之间的弱内在光学对比度以及其缺乏分子特异性。该建议的假设是，新型分子造影剂可以增强OCT成像对比度和早期癌症检测的分子特异性。与其他金属纳米颗粒不同，金纳米笼在近红外范围内表现出非常强的可调谐光学共振，同时保持小尺寸（35-65 nm）。金纳米笼可以为OCT成像提供强度和光谱对比度增强，并且它们允许用于靶向的分子识别剂的容易缀合。具体目标是：（1）使用电流替代纳米化学开发在近红外范围内具有强吸收或散射的金纳米笼，并优化合成条件以用于放大生产;（2）表征纳米笼的光学性质，将结果与基于离散偶极近似的理论计算进行比较，并量化强度和光谱OCT对比度增强;（3）进行体内动物模型研究，以定量评估OCT在生物缀合纳米笼辅助下用于早期癌症检测的能力;以及（4）使用分子造影剂研究OCT在人类食管切除术标本上检测发育异常和早期癌症的能力。如果成功，分子对比OCT可以提高我们检测早期癌症的能力，指导活检和癌症手术。此外，分子造影剂还可用于其他光学成像和光谱技术。